Efficacy of Febuxostat Versus Allopurinol and the Predictors of Achieving Target Serum Urate in a Cohort of Thai People with Gout

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2020 Jul 2

PMID 32607660

Authors

Ratchaya Lertnawapan

Kanon Jatuworapruk

Affiliations

Soon will be listed here.

Abstract

Objective: The objectives of our study were to compare the efficacy of febuxostat with allopurinol in Thai subjects with gout, as well as to determine the predictive factors of responsiveness to urate-lowering agents and to evaluate the safety of febuxostat in a real-world setting.

Methods: The study was a retrospective cohort study; a total of 354 gout patients were recruited from February 2015 to November 2018. The patients were categorized according to prescription of allopurinol or febuxostat. Demographic data, comorbidities, concomitant medications, gout-related clinical parameters, and the laboratory results were collected. The serial serum urate (sUA) levels were recorded at the beginning of the treatment (baseline), and after treatment at 12 weeks, 18 weeks, and 27 weeks. The primary efficacy endpoint was the achievement of target urate of < 6 mg/dl in people taking febuxostat, compared with those taking allopurinol. The secondary endpoints were the predictive factors of achieving target urate level and adverse drug reactions in patients taking febuxostat. Multivariable regression analysis was used to determine factors associated with achieving target serum urate.

Results: After the treatment, the febuxostat groups had significantly lower mean sUA compared with the allopurinol groups across all follow-up periods. The proportion of people who achieved target serum urate was also higher in the febuxostat groups compared with the allopurinol groups throughout the follow-up periods. The multivariable regression analysis showed that febuxostat 40 mg (OR = 10.96 (95% CI 4.32-27.80); p value < 0.001), febuxostat 80 mg (OR = 9.54 (95% CI 3.91-23.28), smoking (OR = 2.35 (95% CI 1.13-4.91); p value = 0.023), and low baseline serum urate (OR = 0.62 (95% CI 0.52-0.74); p value < 0.001) were associated with the achievement of target serum urate. No adverse drug reaction from febuxostat was observed even among people with renal insufficiency.

Conclusion: In a Thai cohort, people receiving febuxostat are more likely to achieve target serum urate level, compared with people receiving allopurinol. Febuxostat (40 or 80 mg), smoking, and low baseline serum urate were associated with the achievement of target serum urate.

Key Points: • Febuxostat showed superior urate-lowering efficacy compared with allopurinol in an Asian population. • In addition to febuxostat, lower baseline serum urate level and history of smoking were associated with achieving target serum urate in gout patients.

References

Singh J, Cleveland J . Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol. 2019; 20(1):93. PMC: 6420755. DOI: 10.1186/s12882-019-1274-5. View

Elfishawi M, Zleik N, Kvrgic Z, Michet Jr C, Crowson C, Matteson E . Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years. J Rheumatol. 2019; 47(4):613-618. PMC: 6960359. DOI: 10.3899/jrheum.190346. View

Towiwat P, Chhana A, Dalbeth N . The anatomical pathology of gout: a systematic literature review. BMC Musculoskelet Disord. 2019; 20(1):140. PMC: 6444644. DOI: 10.1186/s12891-019-2519-y. View

Foody J, Turpin R, Tidwell B, Lawrence D, Schulman K . Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor. Am Health Drug Benefits. 2017; 10(8):393-401. PMC: 5726059. View

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View

Lerch M, Mainetti C, Beretta-Piccoli B, Harr T . Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allergy Immunol. 2017; 54(1):147-176. DOI: 10.1007/s12016-017-8654-z. View

Becker M, Schumacher H, Espinoza L, Wells A, Macdonald P, Lloyd E . The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63. PMC: 2888216. DOI: 10.1186/ar2978. View

Singh J, Akhras K, Shiozawa A . Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015; 17:120. PMC: 4427980. DOI: 10.1186/s13075-015-0624-3. View

Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S . Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6):798-810. DOI: 10.1053/j.ajkd.2018.06.028. View

10.

Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H . Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Med. 2020; 17(4):e1003095. PMC: 7176100. DOI: 10.1371/journal.pmed.1003095. View

11.

Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K . Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019; 40(22):1778-1786. PMC: 6554652. DOI: 10.1093/eurheartj/ehz119. View

12.

Neogi T, Jansen T, Dalbeth N, Fransen J, Schumacher H, Berendsen D . 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10):1789-98. PMC: 4602275. DOI: 10.1136/annrheumdis-2015-208237. View

13.

Becker M, Schumacher H, MacDonald P, Lloyd E, Lademacher C . Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36(6):1273-82. DOI: 10.3899/jrheum.080814. View

14.

Edwards N . Febuxostat : a viewpoint by N. Lawrence Edwards. Drugs. 2008; 68(13):1875-6. DOI: 10.2165/00003495-200868130-00007. View

15.

Jackson R, Hunt B, MacDonald P . The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr. 2012; 12:11. PMC: 3368715. DOI: 10.1186/1471-2318-12-11. View

16.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X . An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014; 17(6):679-86. DOI: 10.1111/1756-185X.12266. View

17.

Nuki G, Doherty M, Richette P . Current management of gout: practical messages from 2016 EULAR guidelines. Pol Arch Intern Med. 2017; 127(4):267-277. DOI: 10.20452/pamw.4001. View

18.

Waller A, Jordan K . Use of febuxostat in the management of gout in the United Kingdom. Ther Adv Musculoskelet Dis. 2017; 9(2):55-64. PMC: 5315226. DOI: 10.1177/1759720X16682010. View

19.

Schumacher Jr H, Becker M, Wortmann R, MacDonald P, Hunt B, Streit J . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59(11):1540-8. DOI: 10.1002/art.24209. View

20.

Koide H, Hira D, Tsujimoto M, Katsube Y, Minegaki T, Uzu T . Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. Biol Pharm Bull. 2017; 40(5):681-686. DOI: 10.1248/bpb.b16-00972. View